HomeCompareMYOV vs O

MYOV vs O: Dividend Comparison 2026

MYOV yields 7.41% · O yields 5.28%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 O wins by $1.6K in total portfolio value· pulled ahead in Year 10
10 years
MYOV
MYOV
● Live price
7.41%
Share price
$26.98
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$32.7K
Annual income
$1,186.18
Full MYOV calculator →
O
Realty Income Corporation
● Live price
5.28%
Share price
$61.18
Annual div
$3.23
5Y div CAGR
15.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$34.2K
Annual income
$5,098.20
Full O calculator →

Portfolio growth — MYOV vs O

📍 O pulled ahead of the other in Year 10

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMYOVO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MYOV + O cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MYOV pays
O pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MYOV
Annual income on $10K today (after 15% tax)
$630.10/yr
After 10yr DRIP, annual income (after tax)
$1,008.25/yr
O
Annual income on $10K today (after 15% tax)
$448.90/yr
After 10yr DRIP, annual income (after tax)
$4,333.47/yr
At 15% tax rate, O beats the other by $3,325.22/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MYOV + O for your $10,000?

MYOV: 50%O: 50%
100% O50/50100% MYOV
Portfolio after 10yr
$33.4K
Annual income
$3,142.19/yr
Blended yield
9.40%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on O right now

MYOV
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
-3.0
Piotroski
2/9
O
Analyst Ratings
13
Buy
18
Hold
3
Sell
Consensus: Hold
Price Target
$64.00
+4.6% upside vs current
Range: $60.00 — $69.00
Altman Z
1.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MYOV buys
0
O buys
0
No recent congressional trades found for MYOV or O in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMYOVO
Forward yield7.41%5.28%
Annual dividend / share$2.00$3.23
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.1%
Portfolio after 10y$32.7K$34.2K
Annual income after 10y$1,186.18$5,098.20
Total dividends collected$9.7K$20.7K
Payment frequencyquarterlymonthly
SectorStockREIT
Analyst consensusBuyHold

Year-by-year: MYOV vs O ($10,000, DRIP)

YearMYOV PortfolioMYOV Income/yrO PortfolioO Income/yrGap
1$11,441$741.29$10,818$607.86+$623.00MYOV
2$13,035$792.65$11,786$741.30+$1.2KMYOV
3$14,791$843.97$12,944$910.50+$1.8KMYOV
4$16,722$895.04$14,343$1,127.28+$2.4KMYOV
5$18,838$945.65$16,053$1,408.17+$2.8KMYOV
6$21,152$995.63$18,167$1,776.65+$3.0KMYOV
7$23,678$1,044.81$20,815$2,266.60+$2.9KMYOV
8$26,428$1,093.05$24,179$2,927.66+$2.2KMYOV
9$29,418$1,140.20$28,521$3,833.95+$897.00MYOV
10← crossover$32,664$1,186.18$34,218$5,098.20$1.6KO

MYOV vs O: Complete Analysis 2026

MYOVStock

Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, which is in Phase II clinical trial for the treatment of female infertility as part of assisted reproduction. Myovant Sciences Ltd. has collaboration with Pfizer Inc. to develop and commercialize relugolix in oncology and women's health. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was incorporated in 2016 and is based in London, the United Kingdom. Myovant Sciences Ltd. is a subsidiary of Sumitovant Biopharma Ltd.

Full MYOV Calculator →

OREIT

Realty Income, The Monthly Dividend Company, is an S&P 500 company dedicated to providing stockholders with dependable monthly income. The company is structured as a REIT, and its monthly dividends are supported by the cash flow from over 6,500 real estate properties owned under long-term lease agreements with our commercial clients. To date, the company has declared 608 consecutive common stock monthly dividends throughout its 52-year operating history and increased the dividend 109 times since Realty Income's public listing in 1994 (NYSE: O). The company is a member of the S&P 500 Dividend Aristocrats index. Additional information about the company can be obtained from the corporate website at www.realtyincome.com.

Full O Calculator →
📬

Get this MYOV vs O comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MYOV vs SCHDMYOV vs JEPIMYOV vs KOMYOV vs MAINMYOV vs STAGMYOV vs ADCMYOV vs NNNMYOV vs VICI

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.